| Trial registration number
|
NCT05185934 |
Full text link
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT05185934
|
First author
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
Ignatios Ikonomidis, Professor
|
Contact
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
ignoik@gmail.com
|
Registration date
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
2022-01-11
|
Recruitment status
Last imported at : Aug. 6, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Recruiting
|
Study design
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
Blind label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
caucasian patients
hospitalization for covid-19 infection
diagnosis of covid-19 proven by pcr
|
Exclusion criteria
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
pregnancy and breastfeeding
foreseen inability to attend scheduled visits
history of acute coronary syndrome. coronary artery disease will be excluded by a clinical history, examination and electrocardiogram.
moderate or severe valve disease
primary cardiomyopathies
chronic obstructive pulmonary disease
asthma
chronic kidney disease (estimated glomerular filtration rate [egfr] ≤60 ml/min/1.73 m2)
liver failure
malignancies
|
Number of arms
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
University of Athens
|
Inclusion age min
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
75
|
Countries
Last imported at : Aug. 6, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Greece
|
Type of patients
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
Moderate/severe/critical disease at enrollment
|
Severity scale
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
5: Moderate/severe/critical disease at enrollment
|
Total sample size
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
60
|
primary outcome
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
Endocalyx effects on endothelial glycocalyx thickness
|
Notes
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
Not reported
|
Arms
Last imported at : Jan. 12, 2022, 9 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "", "treatment_id": 404, "treatment_name": "Dietary supplement", "treatment_type": "Nutrition", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
|